Articles tagged "Kidney transplantation"

2022 American Transplant Congress
Regulatory T Cells Suppress Memory IL-17a Production in Highly Sensitised Patients with End-Stage Renal Disease
C. Dudreuilh¹, S. Basu¹, O. Shaw², H. Burton¹, C. Domingo-Vila¹, T. Tree¹, G. Lombardi¹, C. Scotta¹, A. Dorling¹
¹King's College London, London, United Kingdom, ²Viapath Clinical Transplantation Laboratory, Guy's Hospital, London, United Kingdom
*Purpose: Highly sensitised patients exhibit poorer long-term outcomes following renal transplantation compared to those non sensitised individuals. IL17-A has been associated with acute rejection. Presence…
2022 American Transplant Congress
Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients
Y. Chen¹, J. Ahn¹, N. Chu¹, S. Bae¹, M. A. Schnitzler², G. Hess³, K. Lentine⁴, D. Segev⁵, M. McAdams-DeMarco¹
¹Johns Hopkins School of Medicine, Baltimore, MD, ²Surgery, Saint Louis University, O Fallon, IL, ³Drexel University School of Medicine, Philadelphia, PA, ⁴Saint Louis University, St. Louis, MO, ⁵Johns Hopkins University, Baltimore, MD
*Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…
2022 American Transplant Congress
First-in-human Study Of Lis1, A Novel Glyco-humanized Anti-lymphocyte Swine Polyclonal Antibody, In Kidney Transplantation: Safety And Efficacy
J. Slatinska¹, B. Vanhove², M. Kolarova¹, F. Shneiker², J. Rousse², C. Galli³, J. Bach⁴, E. Cozzi⁵, J. Soulillou⁶, O. Duvaux², O. Viklicky¹
¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Xenothera, Nantes, France, ³Laboratorio di Tecnologie della Riproduzione, Cremone, Italy, ⁴IECM, Immunoendocrinology, USC1383, Oniris, INRAE, Nantes, France, ⁵Transplantation Immunology Unit, Padua University Hospital, Padova, Italy, ⁶Nantes Universités, Nantes, France
*Purpose: to assess safety, T cell depletion, PK/PD and determine the therapeutic dose of LIS1, a purified anti-lymphocyte glyco-humanized polyclonal swine IgG, derived by immunizing…
2022 American Transplant Congress
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
S. S. Patel, P. Jadav, M. Sekulic, S. Kudose, I. Batal, S. Mohan, R. Crew
Columbia University Medical Center, New York, NY
*Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…
2022 American Transplant Congress
Performance of 2021 Creatinine and Cystatin C Based Equations without Race in Living Kidney Transplant Donors
A. Liaqat, H. Sawaf, L. Cholin, S. Arrigain, A. Wee, J. Schold, J. Augustine, E. Poggio
Cleveland Clinic, Cleveland, OH
*Purpose: New 2021 Creatinine (Cr) and Cystatin C (CysC) based GFR equations without the race factor have been refitted to perform better than either 2009…
2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
A. Seghezzo¹, J. Kerr¹, A. Gupta², A. Ta², L. Powell², A. Feist³
¹University of California San Diego Health, San Diego, CA, ²PrecisePK, San Diego, CA, ³UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…
2022 American Transplant Congress
Association of Trugraf GEP with Clinical and Histological Outcomes in a Multicenter Cohort (TOGETHER Study)
R. Heilman¹, W. Park², M. Mai³, B. Smith², R. First⁴, J. Fleming⁴, P. West-Thielke⁴, J. Holman⁴, M. Stegall²
¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Jacksonville, FL, ⁴Transplant Genomics, Framingham, MA
*Purpose: The purpose of this study was to validate the association of TruGraf GEP with clinical endpoints in a real-world cohort.*Methods: This was a multicenter…
2022 American Transplant Congress
Expanding Access to Robotic Kidney Transplantation for Candidates with High BMI. A Training Tool for Transplant Centers
J. A. Almario Alvarez, G. Aguiluz, V. Valle, R. Bustos, S. Akshelyan, A. M. Fratti, P. D. Cocco, M. Spaggiari, I. G. Tzvetanov, E. Benedetti
Surgery, University of Illinois at Chicago, Chicago, IL
*Purpose: Recently published literature has demonstrated favorable outcomes for Robotic Kidney Transplant (RKT) in high BMI recipients. The University of Illinois at Chicago (UIC) has…
2022 American Transplant Congress
Evaluating the Risk and Benefit of Once Daily Delayed Release Mycophenolate in Pediatric Kidney Transplant Recipients
L. Maestretti¹, A. McGrath¹, A. Fong¹, A. Brubaker², A. Gallo³, P. Grimm³, A. Chaudhuri³
¹Pediatric Kidney Transplant, Stanford Children's Health, Palo Alto, CA, ²Transplant Surgery, Stanford University, Palo Alto, CA, ³Stanford University, Palo Alto, CA
*Purpose: Medication non-adherence continues to particularly affect adolescent kidney transplant recipients. Standard immunosuppressive regimen at our center includes tacrolimus, and mycophenolate with or without steroids.…
2022 American Transplant Congress
Delta Changes in Donor-Derived Cell-Free DNA (dd-cfDNA) Complement the Donor Fraction in Kidney Transplant Surveillance
A. Wiseman¹, M. Jagadeesan², G. Gupta³, V. Rao⁴, M. Narayanan⁵, N. Agrawal⁶, G. Shekhtman⁶, Y. Fu⁶, K. Pinney⁶, S. Anand⁷
¹Centura Health, Denver, CO, ²George Washington University, Washington, DC, ³Virginia Commonwealth University, Richmond, VA, ⁴Medical University of South Carolina, Charleston, SC, ⁵Baylor Scott and White, Austin, TX, ⁶CareDx, Brisbane, CA, ⁷Intermountain Healthcare, Murray, UT
*Purpose: Delta changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the…